Healthcare Purchasing News
  • Magazine
  • Continuing Education
  • Webinars
  • Whitepapers
  • Videos
  • Events
  • Hall of Fame
  • Advertise
  • Source Guide
  • Subscribe
  • Sourcing & Logistics
  • Sterile Processing
  • Surgical & Critical Care
  • Patient Satisfaction
  • Infection Prevention
  • EVS & Facility Services
  • Healthcare IT
  • Regulatory
  • Topics
    Sourcing & LogisticsSterile ProcessingSurgical & Critical CarePatient SatisfactionInfection PreventionEVS & Facility ServicesHealthcare ITRegulatory
    Resources
    HPN Source GuideContinuing EducationWebinarsWhitepapersVideosEventsHall of FameAdvertiseAd Specs
    User Tools
    SubscribeContact UsAbout UseNewsletterMagazinesPrivacy PolicyTerms & Conditions
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    1. Infection Prevention

    Moderna data from Phase 2/3 study of COVID-19 vaccine in children, age 6-11

    Oct. 26, 2021
    Photo by August de Richelieu from Pexels
    Pexels August De Richelieu 4261252

    Moderna Inc. has announced positive interim data from a Phase 2/3 study of mRNA-1273, the Company’s vaccine candidate against COVID-19 for children, ages 6-12. This interim analysis showed a robust neutralizing antibody response after two doses of mRNA-1273 at the 50 µg dose level with a favorable safety profile. According to a press release, Moderna plans to submit these data to the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other global regulators in the near term.

    The study, nicknamed KidCOVE is a randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity and effectiveness of two 50 µg doses of mRNA-1273 given to healthy children, 28 days apart. The study population is divided into 3 age groups (6 to <12 years, 2 to <6 years, and 6 months to <2 years).

    This cohort enrolled 4,753 participants who were 6 to less than 12 years of age. In the trial, the SARS-CoV-2-neutralizing antibody geometric mean ratio (GMR) comparing the response in children to the response in young adults from the Phase 3 COVE study was 1.5 (95% Cl: 1.3, 1.8), with a seroresponse rate of 99.3%, representing a difference of 0.6% (95% CI: -2.8%, 2.8%) to the Phase 3 benchmark. These results demonstrate strong immune response in this cohort of children one month after the second dose, and met the co-primary immunogenicity endpoints for 6 to less than 12 years olds in KidCOVE.

    mRNA-1273 was generally well tolerated with a safety and tolerability profile generally consistent with the Phase 3 COVE study in adolescents and adults. The majority of adverse events were mild or moderate in severity. The most common solicited adverse events were fatigue, headache, fever, and injection site pain.

    These data are subject to change based on ongoing data collection. All participants will be monitored for 12 months after their second injection to assess long-term protection and safety.. The Company plans to submit data from the KidCOVE study to a peer-reviewed publication.

    The enrollment for the 6 years to under 12 years is complete, but the Phase 2/3 study continues to enroll children ages 6 months to under 6 years of age. The Company has enrolled approximately 5,700 pediatric participants in the U.S. and Canada in the trial as a whole.

    The study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. For more information, see the press release:

    Moderna release

    More on COVID

    Latest in Infection Prevention

    Photo 3908951 © Salahudin | Dreamstime.com
    Infection Prevention

    WHO Celebrates the Role of Communities in Driving Progress Towards Ending AIDS

    Nov. 30, 2023
    Photo 95060391 © Viktoriya Kuzmenkova | Dreamstime.com
    Infection Prevention

    World Scabies Program achieves milestone in Solomon Islands and Fiji

    Nov. 30, 2023
    1200085423 © deepblue4you | gettyimages.com
    Infection Prevention

    Sanford Health’s Instrument Quality Conundrum

    Janette Wider
    Nov. 28, 2023
    Photo 197864141 © Dizain777 | Dreamstime.com
    Infection Prevention

    WHO sees Uptick of Respiratory Illnesses in Children in Northern China

    Nov. 27, 2023
    Photo 117616099 | Antimicrobial Resistance © Designer491 | Dreamstime.com
    Infection Prevention

    IDSA announces Antimicrobial Stewardship Centers of Excellence designation recipients

    Janette Wider
    Nov. 21, 2023
    Healthcare Purchasing News
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo